Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2024-11-27 00:00:00 ET · period of report 2024-11-25 · accession 0001415889-24-027843 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-11-27 | 2024-11-25+ | SPRY | Chakma Justin | Chief Business Off | S - Sale | $14.12 | -100.0K | 136.4K | -42% | -$1.41M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-25 | S | D | 32,814 | $14.00 | 203,566 | D | — | — | (F1) The weighted average sale price for the transaction reported was $14.0008, and the range of prices were between $14.00 and $14.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 2 | Common | Common Stock | 2024-11-26 | S | D | 42,186 | $14.05 | 161,380 | D | — | — | (F2) The weighted average sale price for the transaction reported was $14.0466, and the range of prices were between $13.95 and $14.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 3 | Common | Common Stock | 2024-11-27 | S | D | 25,000 | $14.39 | 136,380 | D | — | — |